Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Vascular Access Clinical Trials Data Coordinating Center
This study is currently recruiting patients.
Sponsored by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cleveland Clinic Foundation Hospital
Boston University School of Medicine
Duke University
University of Iowa
Maine Medical Center
University of Texas
University of Alabama, Birmingham
Washington University School of Medicine
|
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Purpose
Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae.
Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
Condition | Treatment or Intervention | Phase |
---|---|---|
Kidney Failure |
Drug: Aggrenox Drug: Clopidogrel |
Phase III |
MedlinePlus related topics: Kidney Failure
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: 1) Clopidogrel Prevention of Early AV Fistula Thrombosis (IND 64169) 2) Aggrenox Prevention of Access Stenosis (IND 64,202)
Expected Total Enrollment: 1284
Study start: January 2003;
Study completion: January 2007
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Fistula Study Protocol Inclusion Criteria:
Exclusion Criteria:
Graft Study Protocol Inclusion criteria:
Exclusion Criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |